Summarized by Masters of Longevity from Longevity Technology.
Report on a regenerative cardiology program testing iPSC-derived ventricular cardiomyocyte spheroids for severe heart failure using surgical and catheter delivery approaches.
Key Takeaways
- Heartseed uses high-purity ventricular cardiomyocytes derived from iPS cells organized into cardiomyocyte spheroids.
- One-year clinical results for the open-chest surgical transplantation showed promising safety and efficacy according to the company.
- Heartseed plans to apply for regulatory approval in Japan within 2026 and is enrolling patients for the catheter-based approach.
